S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

Photo of Paul Ausick
By Paul Ausick Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Pills
Thinkstock
The U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s Bayer A.G. to extend the use of the two companies’ blood thinning drug Xarelto for reducing risk of heart attacks and strokes in patients with chest pain or previous cardiac illness. The drug was approved in 2011 for use to prevent clotting during some joint replacement surgeries, and its use has been expanded to treat irregular heartbeats and other types of blood clots.

J&J owns the rights to the drug and Bayer has licensed the rights to market the drug in Europe. Xarelto (rivaroxaban) is one of several drugs being promoted as replacements for warfarin, the standard blood-thinning agent for the past 50 years or so. AstraZeneca PLC (NYSE: AZN) and Eli Lilly & Co. (NYSE: LLY) already have drugs approved to treat what is called acute coronary syndrome.

There should be little impact on share price today, because an FDA panel already had rejected the drug for this expanded use in June of last year. J&J shares set a new 52-week high yesterday and closed up about 0.7%, at $77.20 in a new 52-week range of $61.71 to $77.28.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)
Jeremy Phillips |

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)
"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan
Jeremy Phillips |

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan

Continue Reading

The First 9 Drugs Picked for Biden’s Medicare Price Negotiations
John Harrington |

The First 9 Drugs Picked for Biden’s Medicare Price Negotiations

These medications have been targeted for price negotiations with pharmaceutical companies, the start of the Biden administration’s push to slash…
Chris Lange |

ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms

ThinkstockBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had…
Douglas A. McIntyre |

New Class of Drug-Eluted Stents on the Horizon

by H.S. AyoubBioHealth Investor.com There have been many debates over the last couple of years as to the varying degree…
Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease
Jon C. Ogg |

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its…
Douglas A. McIntyre |

The Next Blockbuster Drugs: A $170 Billion Opportunity

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line…
Douglas A. McIntyre |

Lipitor OTC: What Next? (PFE, MRK, AZN, SNY, BMY, LLY, JNJ, AMGN)

Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability.…
Paul Ausick |

Onyx Pharma Rejects Amgen, but Will Start Search for a Buyer

ThinkstockCancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a…
Jon C. Ogg |

More Than Promising Results for New Heart Drug (BMY, PFE, JNJ, BAYRY, DSKYY, PPH)

A new heart drug aimed a reducing the risk of strokes has outperformed the current drug of choice, warfarin, in…
Douglas A. McIntyre |

Medtronic (MDT): The Stent Business Gets Worse

Medtronic (MDT) has decided to get into the stent business, making the little mesh tubes that keep arteries open. It…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618